Table 3.

Influence of age on the development of long-COVID symptoms in the whole study group and within the individual cohorts of immunocompromised and immunocompetent children

	Prevalence of long-COVID < 12-week post-infection in different age groups
	≤ 1 years old	1–5 years old	6–10 years old	11–15 years old	16–18 years old	p
Whole study group	1 (14.3%)	11 (24.5%)	15 (45.5%)	26 (57.8%)	10 (58.8%)	0.01
ID ( +)	1 (25.0%)	4 (16.7%)	6 (37.5%)	9 (52.9%)	5 (55.6%)	0.01
ID (-)	0 (0.0%)	7 (38.9%)	9 (52.9%)	17 (60.7%)	5 (62.5%)	0.04

	Prevalence of long-COVID > 12-week post-infection in different age groups
	≤ 1 years old	1–5 years old	6–10 years old	11–15 years old	16–18 years old	p
Whole study group	1 (14.29%)	8 (17.78%)	6 (18.18%)	14 (31.11%)	3 (17.65%)	0.24
ID ( +)	1 (25.0%)	3 (12.5%)	1 (6.25%)	2 (11.8%)	1 (11.1%)	0.80
ID (-)	0 (0.0%)	5 (22.7%)	5 (29.4%)	12 (42.9%)	2 (25.0%)	0.18

ID ( +), children with immunodeficiency; ID (-), children without immunodeficiency